Sign In
Buy MRKR
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 20'th May 2026
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
07:45pm, Wednesday, 18'th Mar 2026
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
05:31pm, Wednesday, 18'th Mar 2026
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 18'th Feb 2026
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
09:41am, Wednesday, 21'st Jan 2026
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
10:56am, Wednesday, 07'th Jan 2026
After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective.
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
09:46am, Wednesday, 07'th Jan 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Friday, 14'th Nov 2025
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
07:30am, Wednesday, 05'th Nov 2025
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
07:30am, Monday, 06'th Oct 2025
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Thursday, 28'th Aug 2025
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
12:34pm, Tuesday, 26'th Aug 2025
Marker Therapeutics, Inc. MRKR on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell prod
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
07:00am, Tuesday, 26'th Aug 2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating
